PW52: Ketamine: Therapeutic History and Current Research


Pharmacy Webinar 52

THE PSYCHEDELIC SERIES (PART 4)

Ketamine: Therapeutic History and Current Research

with Natalie Metz, ND, MA



TUESDAY, February 22, 2022
: 6:30 - 8:30pm

2 pharmacy CEs* (approved by CNDA; pending approval by OBNM)

2 CEs for CA LAc* (pending)

REGISTER NOW * $75 members  |  $95 non-members


Ketamine is a unique psychoactive substance known for its analgesic, anesthetic, antidepressant, dissociative, and psychostimulant effects. It was synthesized in 1962, and in 1966 was developed into Ketalar, becoming the most widely used battlefield anesthetic in the Vietnam War. It is distinct in its anesthetic application as it preserves cardiovascular and respiratory function. It is a potent and complex pharmacologic agent, interacting with many receptors, and exhibiting an antagonistic effect at the NMDA receptor, effectively blocking glutamate agonism which has many physiological and phenomenological implications.
 
In the 1970’s ketamine gained the interest of various global therapeutic communities. It has been explored in psychotherapeutic contexts for decades since then, with early research demonstrating benefit in patients navigating problematic substance use. It is currently prescribed as an analgesic and antidepressant in primary care, and also used in the ER for depressed patients with active suicidal ideation. Ketamine is also being explored as an adjunct to psychotherapy in both psycholytic and psychedelic doses in what is known as ketamine assisted or ketamine facilitated psychotherapy.
 
Due to its presence in Schedule III, ketamine is the only legally available prescription psychedelic agent in the US. This both opens the door to creative explorations with on and off-label ketamine prescriptions, as well as invites a conversation about the responsibility and ethics of care associated with its use.
 
This is the fourth of a series of webinars which offers an overview of psychedelic-assisted therapies.

Goals and Objectives:

  • Understand basic neuroscience, pharmacology, and proposed therapeutic mechanisms of action of ketamine
  • Describe basic history of ketamine and use in therapeutic contexts
  • Demonstrate familiarity with past and current research exploring the therapeutic potentials of ketamine-assisted therapies
  • Review the outcomes of select research, demonstrating the overall safety and efficacy of ketamine-assisted therapies



REGISTER NOW

Category 1 TM Credits
CE Provider #805
310 670 8100
This course is pending approval by The California Acupuncture Board for 2 hours of continuing education
This course will be available as a self study after the date of the live webinar. 
*Refunds not available

 

 


   

Dr. Natalie Metz, ND, is a licensed Naturopathic Doctor, herbalist, and faculty member and mentor at the California Institute of Integral Studies and the School of Consciousness Medicine, where she teaches courses on holistic health and psychedelic medicines. She earned a Doctorate in Naturopathic Medicine at Southwest College of Naturopathic Medicine in 2006, and a Master of Arts in Philosophy, Cosmology, and Consciousness in 2014, as well as a Certificate in Psychedelic Therapies and Research in 2016 at CIIS. She serves on the advisory boards for the Limina Foundation and the MAPS Zendo Project. She has a private practice in Oakland, CA, and Santa Fe, NM, where she assists patients in their wellness with the support of plant medicine, diet and lifestyle counseling, and the integration of beyond-ordinary life experiences. She is a lifelong student of dance, a lover of art, travel, and all things purple, and truly enjoys sharing her passion for life with the world.


 
     


Naturopathic Advocates

The CNDA is working to educate state legislative and insurance agencies as well as the public on the benefits of naturopathic medicine. We will continue to build relationships in the naturopathic community in an effort to optimize the impact of the naturopathic doctors in our state.